Open access
Aug 2026
Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
In this real-world study, higher rates of immune-related adverse events were observed than those reported in the KEYNOTE-522 trial, although severe toxicities remained uncommon.
E. Boujeke, Aaron Catalan, L. Arayan et al.
· Current Oncology · 0 citations